SEC Filing Summary: Rexahn Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on September 19, 2016. The report details the closing of a registered direct offering of common stock and warrants. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
- Gross Proceeds: $6.0 million.
- Shares Issued: 24,000,000 shares of common stock.
- Warrants Issued: Warrants to purchase 18,000,000 shares of common stock.
- Warrant Terms: Exercise price of $0.30 per share; issued in units of one share and a warrant for 0.75 of a share.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics as this is a transaction-specific report.
Material Changes
The primary material change is the increase in equity capital and outstanding share count resulting from the closing of the Offering on September 19, 2016. This transaction was previously announced in a Form 8-K filed on September 14, 2016.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal opinion regarding the legality of the issuance. The proceeds are intended to fund the company's operations, though specific allocation details are not provided in this text.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the use of the $6.0 million in gross proceeds as disclosed in subsequent filings or press releases.
- Review the warrant exercise terms ($0.30 strike price) for potential future dilution.
- Check for any underwriting discounts or commissions that may reduce the net proceeds below the $6.0 million gross figure.